ethyl 1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxylate | 1494676-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: ethyl 1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxylate
• 英文别名: 1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid ethyl ester；Ethyl 1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-6-methylpyrrolo[3,2-b]pyridine-3-carboxylate
• CAS: 1494676-28-6
• 化学式: C₁₈H₂₀N₄O₃
• 分子量: 340.382
• InChiKey: DIPYVELYYOIWLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.68
• 重原子数：
  25.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  79.13
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  ethyl 1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxylate 在 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 17.17h， 生成 N-((1-hydroxycyclopropyl)methyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide
  参考文献：
  名称：

  [EN] CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA
  [FR] COMPOSÉS AZAHÉTÉROARYLES CONDENSÉS AYANT UNE ACTIVITÉ ANTIBACTÉRIENNE CONTRE LES BACTÉRIES DE LA TUBERCULOSE

  摘要：

  本发明涉及一般式（I）的新化合物，它们的对映体、非对映体、药学上可接受的盐或其前药，适用于治疗细菌感染。一般式（I）的化合物表现出DprE1酶抑制活性。

  公开号：

  WO2019239382A1
• 作为产物：
  描述：

  2-氯-5-甲基-3-硝基吡啶 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 potassium carbonate 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 51.25h， 生成 ethyl 1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxylate
  参考文献：
  名称：

  [EN] CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA
  [FR] COMPOSÉS AZAHÉTÉROARYLES CONDENSÉS AYANT UNE ACTIVITÉ ANTIBACTÉRIENNE CONTRE LES BACTÉRIES DE LA TUBERCULOSE

  摘要：

  本发明涉及一般式（I）的新化合物，它们的对映体、非对映体、药学上可接受的盐或其前药，适用于治疗细菌感染。一般式（I）的化合物表现出DprE1酶抑制活性。

  公开号：

  WO2019239382A1

文献信息

• 氮杂吲哚酰胺类化合物及其制备方法和用途
  申请人：青岛吉澳医药科技有限公司

  公开号：CN111393435A

  公开（公告）日：2020-07-10

  本发明公开了一类氮杂吲哚酰胺类化合物、其组合物及其制备方法和用途。本发明所述的化合物或组合物具有抑制分枝杆菌的生长或降低分枝杆菌的细菌载量活性的作用，可用于治疗结核病或分枝杆菌感染。
• Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious <i>in Vivo</i>
  作者：Pravin S. Shirude、Radha Shandil、Claire Sadler、Maruti Naik、Vinayak Hosagrahara、Shahul Hameed、Vikas Shinde、Chandramohan Bathula、Vaishali Humnabadkar、Naveen Kumar、Jitendar Reddy、Vijender Panduga、Sreevalli Sharma、Anisha Ambady、Naina Hegde、James Whiteaker、Robert E. McLaughlin、Humphrey Gardner、Prashanti Madhavapeddi、Vasanthi Ramachandran、Parvinder Kaur、Ashwini Narayan、Supreeth Guptha、Disha Awasthy、Chandan Narayan、Jyothi Mahadevaswamy、KG Vishwas、Vijaykamal Ahuja、Abhishek Srivastava、KR Prabhakar、Sowmya Bharath、Ramesh Kale、Manjunatha Ramaiah、Nilanjana Roy Choudhury、Vasan K. Sambandamurthy、Suresh Solapure、Pravin S. Iyer、Shridhar Narayanan、Monalisa Chatterji

  DOI：10.1021/jm401382v

  日期：2013.12.12

  We report 1,4-azaindoles as a new inhibitor class that kills Mycobacterium tuberculosis in vitro and demonstrates efficacy in mouse tuberculosis models. The series emerged from scaffold morphing efforts and was demonstrated to noncovalently inhibit decaprenylphosphoryl-beta-D-ribose2'-epimerase (DprE1). With "drug-like" properties and no expectation of pre-existing resistance in the clinic, this chemical class has the potential to be developed as a therapy for drug-sensitive and drug-resistant tuberculosis.
• Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents
  作者：Pravin S. Shirude、Radha K. Shandil、M. R. Manjunatha、Claire Sadler、Manoranjan Panda、Vijender Panduga、Jitendar Reddy、Ramanatha Saralaya、Robert Nanduri、Anisha Ambady、Sudha Ravishankar、Vasan K. Sambandamurthy、Vaishali Humnabadkar、Lalit K. Jena、Rudrapatna S. Suresh、Abhishek Srivastava、K. R. Prabhakar、James Whiteaker、Robert E. McLaughlin、Sreevalli Sharma、Christopher B. Cooper、Khisi Mdluli、Scott Butler、Pravin S. Iyer、Shridhar Narayanan、Monalisa Chatterji

  DOI：10.1021/jm500571f

  日期：2014.7.10

  In a previous report, we described the discovery of 1,4-azaindoles, a chemical series with excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-beta-D-ribose-2'-epimerase (DprE1). Nevertheless, high mouse metabolic turnover and phosphodiesterase 6 (PDE6) off-target activity limited its advancement. Herein, we report lead optimization of this series, culminating in potent, metabolically stable compounds that have a robust pharmacokinetic profile without any PDE6 liability. Furthermore, we demonstrate efficacy for 1,4-azaindoles in a rat chronic TB infection model. We believe that compounds from the 1,4-azaindole series are suitable for in vivo combination and safety studies.
• Journal of Medicinal Chemistry 2014, 57, 5728-5737
  作者：

  DOI：——

  日期：——
• CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20210292333A1

  公开（公告）日：2021-09-23

  Present invention relates to novel compound of general formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection. The compounds of general formula (I) exhibit DprE1 enzyme inhibitory activity.